Safety of Tenofovir on bone mineral density in HIV- infected youths: a 10-year Study

Bone Mineral Density Changes among HIV-Uninfected Young Adults in a Randomised Trial of Pre-Exposure Prophylaxis with Tenofovir-Emtricitabine or Placebo in Botswana

Kasonde Michael
Niska Richard W.
Rose Charles
Henderson Faith L.
Segolodi Tebogo M.
Turner Kyle
Smith Dawn K.
Thigpen Michael C.
Paxton Lynn A.

March 2014

Tenofovir-emtricitabine (TDF-FTC) pre-exposure prophylaxis (PrEP) has been found to be effective for...

Decline in Bone Mass With Tenofovir Disoproxil Fumarate/Emtricitabine Is Associated With Hormonal Changes in the Absence of Renal Impairment When Used by HIV-Uninfected Adolescent Boys and Young Men for HIV Preexposure Prophylaxis.

Havens, Peter L
Stephensen, Charles B
Van Loan, Marta D
Schuster, Gertrud U
Woodhouse, Leslie R
Flynn, Patricia M
Gordon, Catherine M
Pan, Cynthia G
Rutledge, Brandy
Liu, Nancy
Wilson, Craig M
Hazra, Rohan
Hosek, Sybil G
Anderson, Peter L
Seifert, Sharon M
Kapogiannis, Bill G
Mulligan, Kathleen

February 2017

BackgroundWe aimed to define the relative importance of renal and endocrine changes in tenofovir dis...

renal safety of highly active antiretroviral therapy including tenofovir in vertically HIV-infected youths: a 60-Months longitudinal study

V. Giacomet
Gv. Zuccotti
G. Bedogni
V. Manfredini
S. Coletto
F. Marinacci
A. Viganò

January 2010

renal safety of highly active antiretroviral therapy including tenofovir in vertically HIV-infected ...

Tenofovir disoproxil fumarate and bone mineral density : a 60-month longitudinal study in a cohort of HIV-infected youths

A. Vigan\uf2
G.V. Zuccotti
M. Puzzovio
V. Pivetti
I. Zamproni
C. Cerini
V. Fabiano
V. Giacomet
S. Mora

January 2010

Background: Decreased bone mineral density (BMD) has been associated with the use of tenofovir disop...

A 10-year follow-up of bone mineral density in HIV-infected youths receiving tenofovir disoproxil fumarate

V. Giacomet
K. Maruca
A. Ambrosi
G.V. Zuccotti
S. Mora

September 2017

Background: The use of tenofovir disoproxil fumarate (TDF) has simplified the antiretroviral regimen...

A 12-month treatment with tenofovir does not impair bone mineral accrual in HIV-infected children

V. Giacomet
S. Mora
L. Martelli
M. Merlo
M. Sciannamblo
A. Vigan&#242

January 2005

Background: Short-term use of tenofovir (TDF) has been associated with bone mineral loss in adults a...

BRIEF REPORT: CLINICAL SCIENCE A 12-Month Treatment With Tenofovir Does Not Impair Bone Mineral Accrual in HIV-Infected Children

Mariateresa Sciannamblo

February 2015

Background: Short-term use of tenofovir (TDF) has been associated with bone mineral loss in adults a...

Assessing bone mineral density in children and adolescents living with HIV and on treatment with tenofovir disoproxil fumarate: a systematic review

Maria Brennda Ferreira de Gusmão
Vinícius Vital de Oliveira
Natália Maria da Silva Santos
Luciana Costa Melo

November 2023

ABSTRACT Objective: To investigate the impact of tenofovir disoproxil fumarate on bone mineral dens...

Impact on bone mineral density of tenofovir-containing HAART in HIV-1 infected children and adolescents: a report from 5 years of clinical experience

F. De Terlizzi
A. Parodi
Claudio Viscoli
Francesca Ginocchio
C. Torrisi
Raffaella Rosso
M. Vignolo
A. Di Biagio

January 2008

Purpose of the study Tenofovir disoproxil fumarate (TDF) is not approved for use in HIV-infected chi...

Tenofovir Has Minimal Effect on Biomarkers of Bone Health in Youth with HIV Receiving Initial Antiretroviral Therapy

Kim-Chang, Julie J
Wilson, Lorena
Chan, Cliburn
Fischer, Bernard
Venturi, Guglielmo
Goodenow, Maureen M
Aldrovandi, Grace
Weber, Thomas J
Sleasman, John W
Emmanuel
Lujan-Zilberman
Julian
Belzer
Flores
Tucker
Kovacs
Homans
Lozano
D'Angelo
Hagler
Trexler
Douglas
Tanney
DiBenedetto
Martinez
Bojan
Jackson
Febo
Ayala-Flores
Fuentes-Gomez
Futterman
Enriquez-Bruce
Campos
Steever
Geiger
Moscicki
Auerswald
Irish
Abdalian
Kozina
Baker
Peralta
Gorle
Friedman
Maturo
Major-Wilson
Puga
Leonard
Inman
Flynn
Dillard
Garofalo
Brennan
Flanagan

August 2019

Both HIV infection and tenofovir disoproxil fumarate (TDF) treatment adversely impact bone metabolis...

The Effect of Tenofovir on Vitamin D Metabolism in HIV-Infected Adults Is Dependent on Sex and Ethnicity

Klassen Karen
Martineau Adrian R.
Wilkinson Robert J.
Cooke Graham
Courtney Alan P.
Hickson Mary

September 2012

Tenofovir has been associated with renal phosphate wasting, reduced bone mineral density, and higher...

Bone mineral density changes among HIV-uninfected young adults in a randomised trial of pre-exposure prophylaxis with tenofovir-emtricitabine or placebo in Botswana.

Michael Kasonde
Richard W Niska
Charles Rose
Faith L Henderson
Tebogo M Segolodi
Kyle Turner
Dawn K Smith
Michael C Thigpen
Lynn A Paxton

Tenofovir-emtricitabine (TDF-FTC) pre-exposure prophylaxis (PrEP) has been found to be effective for...

Diagnosis, prevention, and treatment of bone fragility in people living with HIV: a position statement from the Swiss Association against Osteoporosis.

Biver, E.
Calmy, A.
Aubry-Rozier, B.
Birkhäuser, M.
Bischoff-Ferrari, H.A.
Ferrari, S.
Frey, D.
Kressig, R.W.
Lamy, O.
Lippuner, K.
Suhm, N.
Meier, C.

May 2019

Life expectancy of people living with HIV (PLWH) is reaching similar length as in the general popula...

Diagnosis, prevention, and treatment of bone fragility in people living with HIV: a position statement from the Swiss Association against Osteoporosis

Biver, E
Calmy, A
Aubry-Rozier, B
Birkhäuser, M
Bischoff-Ferrari, H A
Ferrari, S
Frey, D
Kressig, R W
Lamy, O
Lippuner, K
Suhm, N
Meier, C

May 2019

Life expectancy of people living with HIV (PLWH) is reaching similar length as in the general popula...

Bone outcomes in virally suppressed youth with HIV switching to tenofovir disoproxil fumarate

Kate Braithwaite
Tristan D. McPherson
Yanhan Shen
Stephen Arpadi
Stephanie Shiau
Gillian Sorour
Karl-Günter Technau
Michael T. Yin

August 2021

Background: Tenofovir disoproxil fumarate (TDF) is included in first-line antiretroviral treatment (...

Bone Mineral Density Changes among HIV-Uninfected Young Adults in a Randomised Trial of Pre-Exposure Prophylaxis with Tenofovir-Emtricitabine or Placebo in Botswana

Kasonde Michael
Niska Richard W.
Rose Charles
Henderson Faith L.
Segolodi Tebogo M.
Turner Kyle
Smith Dawn K.
Thigpen Michael C.
Paxton Lynn A.

March 2014

Tenofovir-emtricitabine (TDF-FTC) pre-exposure prophylaxis (PrEP) has been found to be effective for...

Decline in Bone Mass With Tenofovir Disoproxil Fumarate/Emtricitabine Is Associated With Hormonal Changes in the Absence of Renal Impairment When Used by HIV-Uninfected Adolescent Boys and Young Men for HIV Preexposure Prophylaxis.

Havens, Peter L
Stephensen, Charles B
Van Loan, Marta D
Schuster, Gertrud U
Woodhouse, Leslie R
Flynn, Patricia M
Gordon, Catherine M
Pan, Cynthia G
Rutledge, Brandy
Liu, Nancy
Wilson, Craig M
Hazra, Rohan
Hosek, Sybil G
Anderson, Peter L
Seifert, Sharon M
Kapogiannis, Bill G
Mulligan, Kathleen

February 2017

BackgroundWe aimed to define the relative importance of renal and endocrine changes in tenofovir dis...

renal safety of highly active antiretroviral therapy including tenofovir in vertically HIV-infected youths: a 60-Months longitudinal study

V. Giacomet
Gv. Zuccotti
G. Bedogni
V. Manfredini
S. Coletto
F. Marinacci
A. Viganò

January 2010

renal safety of highly active antiretroviral therapy including tenofovir in vertically HIV-infected ...

Tenofovir disoproxil fumarate and bone mineral density : a 60-month longitudinal study in a cohort of HIV-infected youths

A. Vigan\uf2
G.V. Zuccotti
M. Puzzovio
V. Pivetti
I. Zamproni
C. Cerini
V. Fabiano
V. Giacomet
S. Mora

January 2010

Background: Decreased bone mineral density (BMD) has been associated with the use of tenofovir disop...

A 10-year follow-up of bone mineral density in HIV-infected youths receiving tenofovir disoproxil fumarate

V. Giacomet
K. Maruca
A. Ambrosi
G.V. Zuccotti
S. Mora

September 2017

Background: The use of tenofovir disoproxil fumarate (TDF) has simplified the antiretroviral regimen...

A 12-month treatment with tenofovir does not impair bone mineral accrual in HIV-infected children

V. Giacomet
S. Mora
L. Martelli
M. Merlo
M. Sciannamblo
A. Vigan&#242

January 2005

Background: Short-term use of tenofovir (TDF) has been associated with bone mineral loss in adults a...

BRIEF REPORT: CLINICAL SCIENCE A 12-Month Treatment With Tenofovir Does Not Impair Bone Mineral Accrual in HIV-Infected Children

Mariateresa Sciannamblo

February 2015

Background: Short-term use of tenofovir (TDF) has been associated with bone mineral loss in adults a...

Assessing bone mineral density in children and adolescents living with HIV and on treatment with tenofovir disoproxil fumarate: a systematic review

Maria Brennda Ferreira de Gusmão
Vinícius Vital de Oliveira
Natália Maria da Silva Santos
Luciana Costa Melo

November 2023

ABSTRACT Objective: To investigate the impact of tenofovir disoproxil fumarate on bone mineral dens...

Impact on bone mineral density of tenofovir-containing HAART in HIV-1 infected children and adolescents: a report from 5 years of clinical experience

F. De Terlizzi
A. Parodi
Claudio Viscoli
Francesca Ginocchio
C. Torrisi
Raffaella Rosso
M. Vignolo
A. Di Biagio

January 2008

Purpose of the study Tenofovir disoproxil fumarate (TDF) is not approved for use in HIV-infected chi...

Tenofovir Has Minimal Effect on Biomarkers of Bone Health in Youth with HIV Receiving Initial Antiretroviral Therapy

Kim-Chang, Julie J
Wilson, Lorena
Chan, Cliburn
Fischer, Bernard
Venturi, Guglielmo
Goodenow, Maureen M
Aldrovandi, Grace
Weber, Thomas J
Sleasman, John W
Emmanuel
Lujan-Zilberman
Julian
Belzer
Flores
Tucker
Kovacs
Homans
Lozano
D'Angelo
Hagler
Trexler
Douglas
Tanney
DiBenedetto
Martinez
Bojan
Jackson
Febo
Ayala-Flores
Fuentes-Gomez
Futterman
Enriquez-Bruce
Campos
Steever
Geiger
Moscicki
Auerswald
Irish
Abdalian
Kozina
Baker
Peralta
Gorle
Friedman
Maturo
Major-Wilson
Puga
Leonard
Inman
Flynn
Dillard
Garofalo
Brennan
Flanagan

August 2019

Both HIV infection and tenofovir disoproxil fumarate (TDF) treatment adversely impact bone metabolis...

The Effect of Tenofovir on Vitamin D Metabolism in HIV-Infected Adults Is Dependent on Sex and Ethnicity

Klassen Karen
Martineau Adrian R.
Wilkinson Robert J.
Cooke Graham
Courtney Alan P.
Hickson Mary

September 2012

Tenofovir has been associated with renal phosphate wasting, reduced bone mineral density, and higher...

Bone mineral density changes among HIV-uninfected young adults in a randomised trial of pre-exposure prophylaxis with tenofovir-emtricitabine or placebo in Botswana.

Michael Kasonde
Richard W Niska
Charles Rose
Faith L Henderson
Tebogo M Segolodi
Kyle Turner
Dawn K Smith
Michael C Thigpen
Lynn A Paxton

Tenofovir-emtricitabine (TDF-FTC) pre-exposure prophylaxis (PrEP) has been found to be effective for...

Diagnosis, prevention, and treatment of bone fragility in people living with HIV: a position statement from the Swiss Association against Osteoporosis.

Biver, E.
Calmy, A.
Aubry-Rozier, B.
Birkhäuser, M.
Bischoff-Ferrari, H.A.
Ferrari, S.
Frey, D.
Kressig, R.W.
Lamy, O.
Lippuner, K.
Suhm, N.
Meier, C.

May 2019

Life expectancy of people living with HIV (PLWH) is reaching similar length as in the general popula...

Diagnosis, prevention, and treatment of bone fragility in people living with HIV: a position statement from the Swiss Association against Osteoporosis

Biver, E
Calmy, A
Aubry-Rozier, B
Birkhäuser, M
Bischoff-Ferrari, H A
Ferrari, S
Frey, D
Kressig, R W
Lamy, O
Lippuner, K
Suhm, N
Meier, C

May 2019

Life expectancy of people living with HIV (PLWH) is reaching similar length as in the general popula...

Bone outcomes in virally suppressed youth with HIV switching to tenofovir disoproxil fumarate

Kate Braithwaite
Tristan D. McPherson
Yanhan Shen
Stephen Arpadi
Stephanie Shiau
Gillian Sorour
Karl-Günter Technau
Michael T. Yin

August 2021

Background: Tenofovir disoproxil fumarate (TDF) is included in first-line antiretroviral treatment (...

Bone Mineral Density Changes among HIV-Uninfected Young Adults in a Randomised Trial of Pre-Exposure Prophylaxis with Tenofovir-Emtricitabine or Placebo in Botswana

Kasonde Michael
Niska Richard W.
Rose Charles
Henderson Faith L.
Segolodi Tebogo M.
Turner Kyle
Smith Dawn K.
Thigpen Michael C.
Paxton Lynn A.

March 2014

Tenofovir-emtricitabine (TDF-FTC) pre-exposure prophylaxis (PrEP) has been found to be effective for...

Decline in Bone Mass With Tenofovir Disoproxil Fumarate/Emtricitabine Is Associated With Hormonal Changes in the Absence of Renal Impairment When Used by HIV-Uninfected Adolescent Boys and Young Men for HIV Preexposure Prophylaxis.

Havens, Peter L
Stephensen, Charles B
Van Loan, Marta D
Schuster, Gertrud U
Woodhouse, Leslie R
Flynn, Patricia M
Gordon, Catherine M
Pan, Cynthia G
Rutledge, Brandy
Liu, Nancy
Wilson, Craig M
Hazra, Rohan
Hosek, Sybil G
Anderson, Peter L
Seifert, Sharon M
Kapogiannis, Bill G
Mulligan, Kathleen

February 2017

BackgroundWe aimed to define the relative importance of renal and endocrine changes in tenofovir dis...

renal safety of highly active antiretroviral therapy including tenofovir in vertically HIV-infected youths: a 60-Months longitudinal study

V. Giacomet
Gv. Zuccotti
G. Bedogni
V. Manfredini
S. Coletto
F. Marinacci
A. Viganò

January 2010

renal safety of highly active antiretroviral therapy including tenofovir in vertically HIV-infected ...

Safety of Tenofovir on bone mineral density in HIV- infected youths: a 10-year Study

Abstract

Extracted data

Safety of Tenofovir on bone mineral density in HIV- infected youths: a 10-year Study

Abstract

Extracted data

Related items

Related items